Lipid CME
EXPERT VIDEOCME

Cardiovascular Risk: Assessment and Risk Reduction

Author(s)/Faculty: R. Scott Wright, MD
Release Date: 9/16/2016Expiration Date: 9/15/2018
Credit Type: CMENumber of Credits: 0.25
Content Type: VideoProvider:
Even when using intensive statin monotherapy, many patients fail to achieve all of the desired lipid goals and remain at high residual risk of cardiovascular events. Lowering LDL-C is the primary focus of the management of dyslipidemia in patients with or at risk for cardiovascular disease. However, the American College of Cardiology and the American Heart Association published new guidelines that eliminated specific targets for LDL-C. Yet, all of the guidelines agree that lowering LDL-C levels is a key to lowering the risk for cardiovascular disease. Although statins do not completely remove risk, not all patients can tolerate them, and they are not sufficiently effective in patients with very high plasma levels of LDL-C, such as those with familial hypercholesterolemia or those with elevated plasma levels of lipoprotein(a). Recent advances in the understanding of lipoprotein metabolism have led to the development of the PCSK9 inhibitors and other therapies that lower LDL-C. This CME activity will feature interviews with clinical experts, who will discuss newly released evidence and guidelines regarding cardiovascular risk assessment, best practices when evaluating patients with elevated LDL-C, clinical study data pertaining to the effects of lowering LDL-C beyond evidence-based recommendations, and use of non-statin therapies for the treatment of dyslipidemia in patients who cannot achieve desired target levels.